SYMBIOTEC PHARMALAB LTD (SYMBIOTEC): SYMBIOTEC PHARMALAB Share Price Near 52-Week High as Stock Trades Higher
- September 22, 2026
- Posted by: Harsh Piplani
- Category: News
SYMBIOTEC PHARMALAB Share Price is Rs 1,172.50, up 1.21% from the previous close, and trading close to its 52-week high of Rs 1,187.40 with a market capitalisation of Rs 7,024.8 Cr as of 22 September 2026 at 11:18 AM IST. The move places SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) in the market spotlight because the current price is within a narrow band of the yearly high, while recent company updates give investors fresh context to review. For readers tracking SYMBIOTEC PHARMALAB Share Price Today, the latest Univest figures show a session that opened well below the current level before moving into the upper end of the day’s range. SYMBIOTEC Stock News and SYMBIOTEC Share Price Update searches are likely to focus on the combination of price action, quarterly numbers and valuation metrics rather than any single headline.
What happened today is straightforward: SYMBIOTEC PHARMALAB Share Price moved to Rs 1,172.50 from a previous close of Rs 1,158.45, adding Rs 14.05. The stock opened at Rs 1,088.15, touched a low of Rs 1,088.15 and reached a high of Rs 1,187.40, while turnover stood at Rs 17.1 Cr. That keeps SYMBIOTEC PHARMALAB Share Price Today close to the 52-week peak without turning the event into a new record claim. The key takeaway for SYMBIOTEC Stock News readers is that the latest trading level sits near the upper end of the stock’s one-year range, which is why the share price update is drawing attention across Stock Market Today and Shares Market Today searches. The next section looks at the latest company news that may be linked with the move.
SYMBIOTEC PHARMALAB Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,172.5 |
| Previous Close | Rs 1,158.45 |
| Today's Move | +Rs 14.05 (+1.21%) |
| Open | Rs 1,088.15 |
| High | Rs 1,187.4 |
| Low | Rs 1,088.15 |
| Turnover | Rs 17.1 crore |
| Market Capitalisation | Rs 7,024.8 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,172.5 versus the previous close of Rs 1,158.45, a rise of 1.21%. The stock opened at Rs 1,088.15, reached a high of Rs 1,187.4 and touched a low of Rs 1,088.15.
SYMBIOTEC PHARMALAB Share Price traded at Rs 1,172.50 after moving Rs 14.05 higher, or 1.21%, versus the previous close of Rs 1,158.45. The stock opened at Rs 1,088.15 and traded between Rs 1,088.15 and Rs 1,187.40 during the latest update, which places the current level very close to the 52-week high of Rs 1,187.40. The gap between the current price and the one-year high is narrow, so the event is best described as a near-52-week-high move rather than a fresh all-time milestone. Turnover of Rs 17.1 Cr adds a factual traded-value reference for the day and helps frame the share price update without adding any unsupported interpretation. For readers following SYMBIOTEC PHARMALAB Share Price Live and SYMBIOTEC NSE, the session shows a clear move into the upper end of the daily range. Next, the latest company update provides context for why SYMBIOTEC Stock News is trending today.
Why SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) May Be Moving Today
Recent news reports may be linked to the latest SYMBIOTEC PHARMALAB Share Price move. The company reported first-quarter revenue of Rs 2.1 bn, above Rs 2 bn in the same period last year, and net profit rose to Rs 470 mn from Rs 445 mn year over year. At the same time, EBITDA declined to Rs 592 mn from Rs 623 mn, and EBITDA margin eased to 28.05% from 30.50%. Taken together, the news mix presents both improvement and pressure points, which could coincide with the stock appearing in SYMBIOTEC Share News and Stocks in News searches. Univest data confirms the price event, while the reported quarterly figures provide the latest company backdrop for SYMBIOTEC News Today readers.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,024.8 crore |
| P/E Ratio | 67.73x |
| P/B Ratio | 5.01x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 231.19 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 67.73x, P/B 5.01x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7024.8 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 67.73x, P/B at 5.01x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 231.19, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.52x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 67.73x |
| Benchmark Median P/E | 28.52x |
| Benchmark Average P/E | 41.71x |
| Benchmark P/E Range | 0x to 747.32x |
| Company P/B Ratio | 5.01x |
| Benchmark Median P/B | 2.96x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.65% |
| Company Market Capitalisation | Rs 7,024.8 crore |
| Benchmark Median Market Cap | Rs 729.99 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 67.73x, which is above the benchmark median of 28.52x, a difference of +137.48%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.78%, a difference of -4.75%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.65%, a difference of -9.08%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sanofi India Ltd. | SANOFI | 7,111.86 | 21.89 | 8.58 | 44.5 | 55.46 |
| Bliss GVS Pharma Ltd. | BLISSGVS | 7,234.73 | 51.34 | 5.67 | 12.11 | 17.4 |
| Innova Captab Ltd. | INNOVACAP | 6,756.83 | 43.84 | 6.04 | 13.75 | 15.04 |
| Aarti Pharmalabs Ltd. | AARTIPHARM | 7,443.45 | 36.01 | 3.5 | 8.5 | 10.77 |
| Morepen Laboratories Ltd. | MOREPENLAB | 6,624.76 | 47.71 | 5.15 | 7.96 | 10.19 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 67.73x compared with the displayed peer median of 43.84x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 12.11% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 15.04%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,024.8 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC PHARMALAB
- SYMBIOTEC PHARMALAB Share Price is Rs 1,172.50, which is near the 52-week high of Rs 1,187.40.
- The stock is up 1.21% from the previous close of Rs 1,158.45.
- Turnover stands at Rs 17.1 Cr for the latest update.
- P/E is 67.73 and P/B is 5.01, both above the same-industry median.
- Q1 revenue rose to Rs 2.1 bn and net profit increased to Rs 470 mn, while EBITDA and margin moved lower year over year.
About SYMBIOTEC PHARMALAB
SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is tracked on NSE and BSE under the symbol SYMBIOTEC. Its market capitalisation stands at Rs 7,024.8 Cr, and the latest earnings-related update includes quarterly revenue, EBITDA and net profit figures. For readers following SYMBIOTEC Company News, that is the core context available today: industry classification, market value and the latest quarterly reporting backdrop. Univest places these figures together so that SYMBIOTEC PHARMALAB Share Price can be viewed alongside the company profile and the broader pharmaceutical set.
Frequently Asked Questions
Why is SYMBIOTEC PHARMALAB Share Price near its 52-week high?
Ans. SYMBIOTEC PHARMALAB Share Price is at Rs 1,172.50 against a 52-week high of Rs 1,187.40. The latest quarter brought higher revenue and net profit, while valuation and peer comparisons remain central to tracking the move.
What is SYMBIOTEC PHARMALAB Share Price today?
Ans. SYMBIOTEC PHARMALAB Share Price is Rs 1,172.50, up 1.21% from the previous close of Rs 1,158.45. The stock traded between Rs 1,088.15 and Rs 1,187.40 in the latest update.
What does the latest SYMBIOTEC Stock News show?
Ans. The latest SYMBIOTEC Stock News highlights Q1 revenue of Rs 2.1 bn and net profit of Rs 470 mn, alongside lower EBITDA and a softer margin. Those figures frame the current share price update.
How does SYMBIOTEC PHARMALAB compare with sector benchmarks?
Ans. SYMBIOTEC PHARMALAB trades at a P/E of 67.73 versus the same-industry median of 28.52. Its P/B is 5.01 versus a median of 2.96, while ROE and ROCE are close to the industry middle.
What is SYMBIOTEC PHARMALAB market cap?
Ans. SYMBIOTEC PHARMALAB has a market capitalisation of Rs 7,024.8 Cr. That places it above the same-industry median and below the average market cap across the 199-company benchmark set.
What are the key fundamentals for SYMBIOTEC PHARMALAB Share Price?
Ans. Key fundamentals include P/E of 67.73, P/B of 5.01, ROE of 11.22%, ROCE of 12.41%, EPS of Rs 17.1 and book value of Rs 231.19. Dividend yield is 0.
Which peers are useful for SYMBIOTEC PHARMALAB Share Price comparison?
Ans. Useful peers include Sanofi India, Bliss GVS Pharma, Innova Captab and Aarti Pharmalabs. Their market caps and valuation ratios help position SYMBIOTEC PHARMALAB Share Price within the pharma universe.
Should investors track SYMBIOTEC PHARMALAB Share Price on Univest?
Ans. Univest tracks SYMBIOTEC PHARMALAB Share Price with live levels, valuation ratios, sector data, peer comparison and the latest company news. That makes it a practical place to follow the stock's daily update.
Track SYMBIOTEC PHARMALAB Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Readers can track SYMBIOTEC PHARMALAB Share Price on Univest for live updates, market cap, valuation ratios, sector context, peer comparison, 52-week levels and the latest company news. The platform brings together SYMBIOTEC Share Price Today, SYMBIOTEC Stock News and the latest market insights in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
